EC144 is a potent inhibitor of the heat shock protein 90

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7786-7795

  Shi, Jiandong ^a   Van De Water, Ryan ^a   Hong, Kevin ^a   Lamer, Ryan B ^a   Weichert, Kenneth W ^a   Sandoval, Cristina M ^a   Kasibhatla, Srinivas R ^a   Boehm, Marcus F ^a   Chao, Jianhua ^a   Lundgren, Karen ^a   Timple, Noelito ^a   Lough, Rachel ^a   Ibanez, Gerardo ^a   Boykin, Christina ^a   Burrows, Francis J ^a   Kehry, Marilyn R ^a   Yun, Theodore J ^a   Harning, Erin K ^a   Ambrose, Christine ^a   Thompson, Jeffrey ^a   Bixler, Sarah A ^a   Dunah, Anthone ^a   Snodgrass Belt, Pamela ^a   Arndt, Joseph ^a   Enyedy, Istvan J ^a   Li, Ping ^a   Hong, Victor S ^a   McKenzie, Andres ^a   Biamonte, Marco A ^a   more..

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2 AMINO 4 CHLRO 7 [(4 METHOXY 3,5 DIMETHYLPYRIDIN 2 YL)METHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 5 YL] 2 METHYLPENT 4 YN 2 OL; ANTINEOPLASTIC AGENT; BIIB 021; EC 144; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL STRAIN MCF 7; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SPLEEN; STOMACH TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

HSP90 HEAT-SHOCK PROTEINS; HUMANS; PYRIMIDINES; PYRROLES; X-RAY DIFFRACTION;

EID: 84866309629     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300810x     Document Type: Article

References (47)

1. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 2012, 18, 64-76
2. Massey, A. J. ATPases as drug targets: insights from heat shock proteins 70 and 90 J. Med. Chem. 2010, 53, 7280-7286
3. Biamonte, M. A.; Van De Water, R.; Perret, D.; Arndt, J. W.; Scannevin, R. H.; Lee, W.-C. Heat shock protein 90: Inhibitors in clinical trials J. Med. Chem. 2010, 53, 3-17
4. HSP90 Interactors. http://www.picard.ch/downloads/Hsp90interactors.pdf.
5. Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F.; Doty, J. L.; Muzzi, M. L.; DiOrio, C. I.; Barbacci, E. G.; Miller, P. E.; Pollack, V. A.; Savage, D. M.; Sloan, D. E.; Pustilnik, L. R.; Moyer, J. D.; Moyer, M. P. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships J. Med. Chem. 1995, 38, 3813-3820
6. Ge, J.; Normant, E.; Porter, J. R.; Ali, J. A.; Dembski, M. S.; Gao, Y.; Georges, A. T.; Grenier, L.; Pak, R. H.; Patterson, J.; Sydor, J. R.; Tibbits, T. T.; Tong, J. K.; Adams, J.; Palombella, V. J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17- demethoxygeldanamycin as potent, water-soluble inhibitors of HSP90 J. Med. Chem. 2006, 49, 4606-4615 (Pubitemid 44162687)
7. Glaze, E. R.; Smith, A. C.; Johnson, D. W.; McCormick, D. L.; Brown, A. B.; Levin, B. S.; Krishnaraj, R.; Lyubimov, A.; Egorin, M. J.; Tomaszewski, J. E. Dose range-finding toxicity studies of 17-DMAG Proc. Am. Assoc. Cancer Res. 2003, 44, 162-162
8. Eiseman, J. L.; Lan, J.; Lagatutta, T. F.; Hamburger, D. R.; Joseph, E.; Covey, J. M.; Egorin, M. J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts Cancer Chemother. Pharmacol. 2005, 55, 21-32 (Pubitemid 40064492)
9. IPI-493, a Potent, Orally Bioavailable Hsp90 Inhibitor of the Ansamycin Class. http://infi.com/pipeline-archives/IPI-493%20EORTC%202008.pdf.
10. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K.-M. J.; Collins, I.; Davies, N. G. M.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-Diarylisoxazole HSP90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J. Med. Chem. 2008, 51, 196-218
11. Woodhead, A. J; Angove, H.; Carr, M. G.; Chessari, G.; Congreve, M.; Coyle, J. E.; Cosme, J.; Graham, B.; Day, P. J.; Downham, R.; Fazal, L.; Feltell, R.; Figueroa, E.; Frederickson, M.; Lewis, J.; McMenamin, R.; Murray, C. W.; O'Brien, M. A.; Parra, L.; Patel, S.; Phillips, T.; Rees, D. C.; Rich, S.; Smith, D.-M.; Trewartha, G.; Vimkovic, M.; Williams, B.; Woolford, A. J. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-yl- methyl)-1,3-dihydroisondol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design J. Med. Chem. 2010, 53, 5956-5969
12. Ying, W.; Du, Z.; Sun, L.; Foley, K. P.; Proia, D. A.; Blackman, R. K.; Zhou, D.; Inoue, T.; Tatsuta, N.; Sang, J.; Ye, S.; Acquaviva, J.; Ogawa, L. S.; Wada, Y.; Barsoum, J.; Koya, K. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy Mol. Cancer Ther. 2012, 11, 475-484
13. Nakashima, T.; Ishii, T.; Tagaya, H.; Seike, T.; Nakagawa, H.; Kanda, Y.; Akinaga, S.; Soga, S.; Shiotsu, Y. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells Clin. Cancer Res. 2010, 16, 2792-2802
14. Immormino, R. M; Kang, Y.; Chiosis, G.; Gewirth, D. T. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors J. Med. Chem. 2006, 49, 4953-4960 (Pubitemid 44201053)
15. Caldas-Lopes, E.; Cerchietti, L.; Ahn, J. H.; Clement, C. C.; Robles, A. I.; Rodina, A.; Moulick, K.; Taldone, T.; Gozman, A.; Guo, Y.; Wu, N.; de Stanchina, E.; White, J.; Gross, S. S.; Ma, Y.; Varticovski, L.; Melnick, A.; Chiosis, G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 8368-8373
16. Bao, R.; Lai, C.-J.; Qu, H.; Wang, D.; Yin, L.; Zifcak, B.; Atoyan, R.; Wang, J.; Samson, M.; Forrester, J.; Della Rocca, S.; Xu, G.-X.; Tao, X.; Zhai, H.-X.; Cai, X.; Qian, C. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy Clin. Cancer Res. 2009, 15, 4046-4057
17. Evaluation of the Pharmacokinetics and Efficacy of a Novel Pro-Drug of the HSP90 Inhibitor. http://www.myriadpharma.com/images/stories/product- pipeline/mpc-3100/AACR%202011/aacr-2011-abst3237-mpc-3100-prodrug-mpc-0767.pdf.
18. Fadden, P.; Huang, K. H.; Veal, J. M.; Steed, P. M.; Barabasz, A. F.; Foley, B.; Hu, M.; Partridge, J. M.; Rice, J.; Scott, A.; Dubois, L. G.; Freed, T. A.; Silinski, M. A.; Barta, T. E.; Hughes, P. F.; Ommen, A.; Ma, W.; Smith, E. D.; Spangenberg, A. W.; Eaves, J.; Hanson, G. J.; Hinkley, L.; Jenks, M.; Lewis, M.; Otto, J.; Pronk, G. J.; Verleysen, K.; Haystead, T. A.; Hall, S. E. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90 Chem. Biol. 2010, 17, 686-694
19. Kasibhatla, S. R.; Hong, K.; Biamonte, M. A.; Busch, D. J.; Karjian, P. L.; Sensintaffar, J. L.; Kamal, A.; Lough, R. E.; Brekken, J.; Lundgren, K.; Grecko, R.; Timony, G. A.; Ran, Y.; Mansfield, R.; Fritz, L. C.; Ulm, E.; Burrows, F. J.; Boehm, M. F. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity J. Med. Chem. 2007, 50, 2767-2778 (Pubitemid 46980848)
20. Menezes, D. L.; Taverna, P.; Jensen, M. R.; Abrams, T.; Stuart, D.; Yu, G. K.; Duhl, D.; Machajewski, T.; Sellers, W. R.; Pryer, N. K.; Gao, Z. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo Mol. Cancer Ther. 2012, 11, 730-739
21. For another series, also from Novartis, see the following: Massey, A. J.; Schoepfer, J.; Brough, P. A.; Brueggen, J.; Chene, P.; Drysdale, M. J.; Pfaar, U.; Radimerski, T.; Ruetz, S.; Schweitzer, A.; Wood, M.; Garcia-Echeverria, C.; Jensen, M. R. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800 Mol. Cancer Ther. 2010, 9, 906-919
22. Modi, S.; Stopeck, A.; Linden, A.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; Ma, W.; Patil, S.; Norton, L.; Hannan, A. L.; Hudis, C. Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with Her-2 positive metastatic breast cancer progressing on trastuzumab Clin. Cancer Res. 2011, 17, 5132-5139
23. Wong, K. K.; Koczywas, M.; Goldman, J. W.; Paschold, E. H.; Horn, L.; Lufkin, J. M.; Kepros, J.; Teofilici, F.; Shapiro, G.; Socinski, M. A. An Open-Label Phase II Study of the Hsp90 Inhibitor Ganetespib. (STA-9090) as Monotherapy in Patients with Advanced NSCLC. Presented at the ASCO Annual Meeting, 2011; http://www.syntapharma.com/Documents/Ganetespib- Phase%202%20NSCLC-Shapiro-ASCO%202011.pdf.
24. Sequist, L. V.; Gettinger, S.; Senzer, N. N.; Martins, R. G.; Jänne, P. A.; Lilenbaum, R.; Gray, J. E.; Iafrate, A. J.; Katayama, R.; Hafeez, N.; Sweeney, J.; Walker, J. R.; Fritz, C.; Ross, R. W.; Grayzel, D.; Engelman, J. A.; Borger, D. R.; Paez, G.; Natale, R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer J. Clin. Oncol. 2010, 28, 4953-4960
25. Katayama, R.; Khan, T. M.; Benes, C.; Lifshits, E.; Ebi, H.; Rivera, V. M.; Shakespeare, W. C.; Iafrate, A. J.; Engelman, J. A.; Shaw, A. T. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 7535-7540
26. Richardson, P G.; Chanan-Khan, A. A.; Lonial, S.; Krishnan, A. Y.; Carroll, M. P.; Alsina, M.; Albitar, M.; Berman, D.; Messina, M.; Anderson, K. C. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study Br. J. Haematol. 2011, 153, 729-740
27. Richardson, P. G.; Mitsiades, C. S.; Laubach, J. P.; Lonial, S.; Chanan-Khan, A. A; Anderson, K. C. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers Br. J. Haematol. 2011, 152, 367-379
28. Yin, Z.; Zhang, H.; Lundgren, K.; Wilson, L.; Burrows, F.; Shores, C. G. BIIB021, a novel Hsp90 inhibitor, sensitized head and neck squamous cell carcinoma to radiotherapy Int. J. Cancer 2010, 126, 1216-1225
29. Infante, J.; Weiss, G.; Jones, S.; Tibes, R.; Bendell, J.; Brega, N.; Torti, V.; Von Hoff, D.; Burris, H., III; Ramanathan, R. Phase 1 dose escalation study of the oral heat shock protein 90 (Hsp90) inhibitor PF-04929113/SNX-5422 (PF-113) and its associated ocular toxicity EJC Suppl. 2010, 8, 119
30. Huang, K. H.; Eaves, J.; Veal, J.; Barta, T.; Lifeng, G.; Hinkley, L.; Hanson, G. Tetrahydroindolone and Tetrahydroindazolone Derivatives, WO 2006/091963, 2006.
31. Huang, K. H.; Eaves, J.; Veal, J.; Hall, S. E.; Barta, T. E.; Hanson, G. J. Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives. US 2007/0207984, 2007.
32. Lundgren, K.; Zhang, H.; Brekken, J.; Huser, N.; Powell, R. E.; Timple, N.; Busch, D. J.; Neely, L.; Sensintaffar, J. L.; Yang, Y.-C.; McKenzie, A.; Friedman, J.; Scannevin, R.; Kamal, A.; Hong, K.; Kasibhatla, S. R.; Boehm, M. F.; Burrows, F. J. BIIB021, an orally available, fully synthetic small molecule inhibitor of the heat shock protein HSP90 Mol. Cancer Ther. 2009, 8, 921-929
33. Miller, D. J.; Ravikumar, K.; Shen, H.; Suh, J.-K.; Kerwin, S. M.; Robertus, J. D. Structure-based and characterization of novel platforms for ricin and shiga toxin inhibition J. Med. Chem. 2002, 45, 90-98 (Pubitemid 34038544)
34. Taylor, E. C.; Kuhnt, D.; Shih, C.; Rinzel, S. M.; Grindey, G. B.; Barredo, J.; Jannatipour, M.; Moran, R. G. A dideazatetrahydrofolate analog lacking a chiral center at C-6: N -[4-[2-(2-amino-3,4-dihydro-4-oxo-7 H -pyrrolo[2,3- d ]pyrimidin-5yl)ethyl[benzoyl]- l -glutamic acid is an inhibitor of thymidylate synthase J. Med. Chem. 1992, 35, 4450-4454
35. Gangjee, A.; Yu, J.; Kisliuk, R. L.; Haile, W. H.; Sobrero, G.; McGuire, J. J. Design, synthesis, and biological activities of classical N -{4-[2-(2-amino-4-ethylpyrrolo[2,3- d ]pyrimidin-5-yl)ethyl]benzoyl}- l -glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase as potential antitumor agents J. Med. Chem. 2003, 46, 591-600 (Pubitemid 36182760)
36. Shih, C.; Gossett, L. S. The synthesis of N -{2-amino-4-substituted [(pyrrolo[2,3- d ]pyrimidin-5-yl)ethyl]benzoyl}- l -glutamic acids as antineoplastic agents Heterocycles 1993, 35, 825-841
37. Seela, F.; Peng, X. Regioselective syntheses of 7-halogenated 7-deazapurine nucleosides related to 2-amino-7-deaza-2′-deoxyadenosine and 7-deaza-2′-deoxyisoguanosine Synthesis 2004, 1203-1210 (Pubitemid 38789300)
38. Barnett, C. J.; Kobierski, M. E. A convenient method for regioselective C-5 halogenation of 4(3 H)-oxo-7 H -pyrrolo[2,3- d ]pyrimidines J. Heterocycl. Chem. 1994, 31, 1181-1183
39. Tu, Y. Q.; Huebener, A.; Zhang, H.; Moore, C. J.; Fletcher, M. T.; Hayes, P.; Dettner, K.; Francke, W.; McErlean, C. S. P.; Kitching, W. Synthesis and stereochemistry of insect derived spiroacetals with branched carbon skeletons Synthesis 2000, 13, 1956-1978
40. Yun, T. J.; Harning, E. K.; Giza, K.; Rabah, D.; Li, P.; Arndt, J. W.; Luchetti, D.; Biamonte, M. A.; Shi, J.; Lundgren, K.; Manning, A.; Kehry, M. R. EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity J. Immunol. 2011, 186, 563-575
41. Huang, Y.; Blower, P. E.; Liu, R.; Dai, Z.; Pham, A. N.; Moon, H.; Fang, J.; Sadée, W. Chemogenomic analysis indentifies geldanamycins as substrated and inhibitors of ABCB1 Pharm. Res. 2007, 9, 1702-1712 (Pubitemid 47206620)
42. Zhang, H.; Neely, L.; Yang, Y.-C.; Timple, N.; Burrows, F. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance Int. J. Cancer 2009, 126, 1226-1234
43. Luo, W.; Rodina, A.; Chiosis, G. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? BMC Neurosci. 2008, 9 (Suppl. 2) S7
44. Luo, W.; Dou, F.; Rodina, A.; Chip, S.; Kim, J.; Zhao, Q.; Moulick, K.; Aguirre, J.; Wu, N.; Greengard, P.; Chiosis, G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 9511-9516 (Pubitemid 47185810)
45. Dickey, C. A.; Dunmore, J.; Lu, B.; Wang, J.-W.; Lee, W. C.; Kamal, A.; Burrows, F.; Eckman, C.; Hutton, M.; Petrucelli, L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites FASEB J. 2006, 20, 753-755 (Pubitemid 46671204)
46. Dickey, C. A.; Eriksen, J.; Kamal, A.; Burrows, F.; Kasibhatla, S.; Eckman, C. B.; Hutton, M.; Petrucelli, L. Development of a high throughput drug screening assay for the detection of changes in tau levels-proof of concept with HSP90 inhibitors Curr. Alzheimer Res. 2005, 2, 231-238 (Pubitemid 40862886)
47. Salminen, A.; Ojala, J.; Kaarniranta, K.; Hiltunen, M.; Soininen, H. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease Prog. Neurobiol. 2011, 93, 99-110